Introduction
============

Quorum sensing (QS) is a bacterial intercellular communication process, which relies on the synthesis and secretion of signal molecules ([@B24]; [@B27]). The binding of these molecules to specific effectors mediates the regulation of the expression of major virulence factors such as proteases, siderophores, and toxins ([@B26]) and enhances the ability of bacteria to form biofilm. This last characteristic greatly impairs the diffusion of antibiotics enhancing resistance to antibacterial compounds. In this way, QS can be considered a good candidate drug target, as the interference with this pathway makes bacteria less virulent ([@B18]).

This strategy could be particularly useful for the treatment of opportunistic pathogens, such as *Burkholderia cenocepacia*, a Gram negative bacterium which colonizes the lung of cystic fibrosis patients ([@B10]). These infections are particularly dangerous. This is due to the high rate of resistance to antibiotics caused by enzymatic inactivation, modification of target, poor cell wall permeability, and the presence of many efflux pumps ([@B22]). Thus, the identification of new compounds able to inhibit *B. cenocepacia* growth, as well as of new drug targets, is a prominent question.

*B. cenocepacia* J2315 possesses four QS systems composed by a synthase (I) and a receptor (R): CepIR, CciIR, the *Burkholderia* Diffusible Signal Factor (BDSF)-based system RpfF~BC,~ and the recently discovered non-ribosomal peptide synthetase-like cluster *ham* ([@B6]; [@B25]; [@B14]). The characterization of *B. cenocepacia* mutants lacking the synthases CepI and/or CciI and RpfF~BC~ demonstrated an involvement of CepI in biofilm formation, protease production, and virulence, as well as an interplay among the Acyl Homoserine Lactone (AHL) systems CepIR and CciIR and the BDSF-based system ([@B27]).

We recently identified new diketopiperazine molecules, able to inhibit CepI *in vitro*, impairing the ability of *B. cenocepacia* to produce proteases, siderophores, and to form biofilm ([@B21]). These molecules did not possess any antimicrobial activity, nevertheless their administration significantly increased the survival of *Caenorhabditis elegans* nematodes infected with *B. cenocepacia*, suggesting that the virulence of the strain could be attenuated *in vivo*. All these data suggest the possibility of a combined treatment by using CepI inhibitors with antimicrobials, to improve the therapeutic strategies available against *B. cenocepacia* ([@B21]).

The current lack of molecular structure data on CepI prevents the possibility of 3D structure-assisted optimization studies of these new inhibitors. In our previous work, we generated a CepI homology model, and used it to perform *in silico* docking analyses of the diketopiperazine inhibitor 8b (**Figure [1](#F1){ref-type="fig"}**) ("Supplementary Materials and Methods"). Using this approach, we identified multiple candidate binding sites, localized far from the enzyme catalytic site, but in regions possibly still implicated in substrate recognition and catalysis ([@B21]).

![Chemical structure of the (3S)-3-Benzyl-6-(3,6-dioxocyclohexa-1,4-dien-1-yl)piperazine-2,5-dione (8b) CepI inhibitor.](fphar-09-00836-g001){#F1}

Here, we confirmed that the cellular effects of 8b are indeed related to the inhibition of CepI, by analyzing the proteome of *B. cenocepacia* cells treated with the compound, and compared with that of the knock-out *cepI* strain. Moreover, we exploited a site-directed mutagenesis strategy to better define the crucial amino acid residues responsible for catalysis and recognition of the 8b inhibitor. Taken together, our results suggest a possible mechanism of CepI inhibition by the 8b compound through perturbations of a flexible loop involved in recognition and stabilization of the *S*-adenosylmethionine substrate, facilitating future drug discovery approaches based on the 8b chemical scaffold.

Materials and Methods {#s1}
=====================

Site-Directed Mutagenesis
-------------------------

Plasmid pETSUMO-CepI ([@B21]) was used as template for each PCR mutagenesis experiment to generate amino acid substitutions using the primers listed in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. The site-directed mutagenesis was carried out as previously described in the PCR-based method ([@B2]) using HotStar HiFidelity Polymerase (Qiagen) according to manufacturer's instructions.

Proteins Purification and Characterization
------------------------------------------

Wild type and mutant CepI were expressed in *Escherichia coli* BL21(DE3) cells and purified as previously described ([@B21]).

Far-UV circular dichroism (CD) measurements were performed with a JascoJ-700 spectropolarimeter (Jasco-Europe, Cremella, Italy) using a 1 mm path cell. Scans were conducted between 190 and 250 nm at a speed of 50 nm/min with a spectral band width of 2 nm and a sensitivity of 20 mdeg. CD spectrum measurements were performed at 25°C in 50 mM sodium phosphate pH 8.0, 50 mM KCl, and represent the average of 10 scans. The protein concentration was 4--5 μM. Spectra were analyzed using the DichroWeb online platform ([@B29]).

CepI activity was determined according to [@B4]. Reaction mixtures contained 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 0.005% Nonidet P-40, 0.13 mM 2,6-dichlorophenylindophenol (DCPIP), 70 μM Octanoyl-ACP (C8-ACP, prepared as reported previously) ([@B17]; [@B8]), 40 μM *S*-adenosyl methionine (SAM), 4 μM CepI.

Steady-state kinetic parameters were determined by assaying the enzymes at eight different concentrations of substrates, using the Michaelis--Menten equation and Origin eight software.

IC~50~ was determined measuring the enzyme activity in presence of different concentrations of compound, and values determined with the following equation ([@B7]), where A~\[I\]~ is the enzyme activity at inhibitor concentration \[I\] and A~\[0\]~ is the enzyme activity without inhibitor.
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Proteomics Analysis
-------------------

*Burkholderia cenocepacia* Δ*cepI* ([@B27]) and J2315 (with or without 25 μM of 8b compound) were grown in 10 ml of LB medium until OD~600~ ~nm~ \> 2. Cells were then harvested, resuspended in 0.2 ml of Tris-HCl 50 mM, pH 7.5, disrupted by sonication, and centrifuged at 12,000 rpm for 1 h at 4°C.

The amount of proteins present in the supernatant was quantified by bicinchoninic acid method ([@B23]), then 300 μg were precipitated with 10% (v/v) trichloroacetic acid. The obtained protein pellet was dissolved in 125 μL of rehydration buffer (8 M urea, 4% CHAPS (w/v), 65 mM DTE, 0.8% carrier ampholytes (v/v) and 0.5% bromophenol blue) and loaded onto 7 cm IPG strips, with nonlinear pH 3--10 gradient range (GE Healthcare), and strips rehydrated for 1 h at 20°C. The first-dimensional IEF was carried out at 15°C using an Ettan IPGphor system (GE Healthcare), by applying 30 V for 8 h, 120 V for 1 h, 500 V for 0.5 h, 1000 V for 0.5 h and 5000 V for 6 h, for a total of 29--30 kVh. The focused IPG strips were subjected to reduction/alkylation steps then loaded onto an 8 × 6 cm slabs, 12.5% SDS polyacrylamide gels. The 2-DE gels were stained with "Blue silver" (colloidal Coomassie G-250 staining), according to [@B3]. Digital images of stained gels were acquired using VersaDoc Imaging Model 3000 (BioRad) and then subjected to quali/quantitative analysis using the PD Quest (BioRad) version 8.0.1 software. Scanned images were filtered and smoothed to remove background noise, vertical/horizontal streaking, gel artifacts and then normalized to eliminate the variability of each sample. The software then determined the amount of spots present and calculated their intensity by applying the following algorithm: peak value (ODs/image units) ^∗^σ~*x*~^∗^σ~y~ (standard deviations in x and y).

For protein identification, the selected spots were carefully excised from the gel, washed twice with 100 mM ammonium bicarbonate buffer pH 7.8, 50% acetonitrile (ACN) and kept under stirring overnight, until complete destaining. After dehydration, gels were rehydrated by addition of 50 μL of 100 mM ammonium bicarbonate buffer pH 7.8, containing 20 ng/μL sequencing grade trypsin (Promega, Madison, WI, United States) and digestion was performed overnight at 37°C. The resulting peptides were extracted sequentially from gel matrix by treatment with 50 μL of 50% ACN in water, 5% trifluoroacetic acid and finally with 50 μL of 100% ACN. Each extraction involved 15 min of stirring followed by centrifugation and removal of the supernatant. The original supernatant and those obtained from sequential extractions were pooled, dried and stored at −80°C until mass spectrometric analysis. At the moment of use, the peptide mixture was solubilized in 100 μL of 0.1% formic acid (FA) for MS analyses.

The analyses were carried out on an LC-MS (Thermo Finnigan, San Jose, CA, United States) system consisting of a thermostated column oven Surveyor autosampler controlled at 25°C; a quaternary gradient Surveyor MS pump equipped with an UV/V is detector and an Ion Trap (LCQ Fleet^TM^) mass spectrometer with electrospray ionization ion source controlled by Xcalibur software 2.0.7. Analytes were separated by RP-HPLC on a Jupiter (Phenomenex, Torrance, CA, United States) C~18~ column (150 × 2 mm, 4 μm, 90 Å particle size) using a linear gradient (2--60% solvent B in 60 min) in which solvent A consisted of 0.1% aqueous FA and solvent B of ACN containing 0.1% FA. Flow-rate was 0.2 mL/min. Mass spectra were generated in positive ion mode under constant instrumental conditions: source voltage 5.0 kV, capillary voltage 46 V, sheath gas flow 20 (arbitrary units), auxiliary gas flow 10 (arbitrary units), sweep gas flow 1 (arbitrary units), capillary temperature 210°C, tube lens voltage 105 V. MS/MS spectra, obtained by CID studies in the linear ion trap, were performed with an isolation width of 3 Da *m/z*, the activation amplitude was 35% of ejection RF amplitude that corresponds to 1.58 V.

Data processing was performed using Peaks Studio version 4.5 software. The mass list was searched against the SwissProt protein and *B. cenocepacia* databases, under continued mode (MS plus MS/MS) with the following parameters: trypsin specificity; five missed cleavages; peptide tolerance at 0.2 Da and MS/MS tolerance at 0.25 Da; peptide charge 1, 2, 3+ and experimental mass values: monoisotopic.

Results
=======

Diketopiperazine 8b Treatment and *cepI* Knock-Out Have the Same Phenotypic Effects
-----------------------------------------------------------------------------------

In a previous study, we identified a diketopiperazine molecule active against the QS synthase CepI, and impairing the production of virulence factors in *B. cenocepacia* J2315, as well as the ability of the bacterium to form biofilm ([@B21]).

To further confirm that the compound acts also intracellularly inhibiting the CepI synthase, we compared the proteomes of the wild type *B. cenocepacia* J2315 untreated and treated with 25 μM 8b, with that of the Δ*cepI* knock-out strain. To identify the bacterial proteins differentially expressed, parallel 2-DE analyses of protein extracts from each cell lysate were performed in triplicate. **Figures [2A--C](#F2){ref-type="fig"}** shows the representative maps of the three samples.

![Representative 2-DE map of *B. cenocepacia* J2315 untreated **(A)**, treated with 8b 25 μM **(B)** and of Δ*cepI* knock-out strain **(C)**. **(D)** represents the High Master Gel, a virtual image resulting from the correlation of the master gels of each sample group. Red circle highlight the spot corresponding to the giant cable pilus protein.](fphar-09-00836-g002){#F2}

A match set was then created to compare the gels of each replicate and to match the spots present, and used to get a synthetic image (Master Gel) containing qualitative and quantitative data relative to all spots. The Master Gels from each group (*B. cenocepacia* J2315 untreated and treated, and Δ*cepI*) were matched to create a virtual image (High Master Gel, **Figure [2D](#F2){ref-type="fig"}**), containing all the common and uncommon spots. This higher match set allowed to determine the presence or absence of spots and the intensity values of common ones; typically, a mean of 240 protein spots were detected in each gel. The comparison of the 2-DE patterns revealed qualitative and quantitative differences between the three groups considered. In terms of presence/absence, the majority of spots were in common between *B. cenocepacia* J2315 cells treated with 8b and Δc*epI* cells, while protein spots showed different density compared with the untreated J2315. Among them, one protein spot (marked in red in **Figure [2D](#F2){ref-type="fig"}**) showed higher density in 8b treated cells and Δ*cepI* profiles, and was excised from the gel for LC-MS/MS identification. This spot was found to correspond to the giant cable pilus protein CblA (Supplementary Table [S2](#SM1){ref-type="supplementary-material"}), which is known to contribute to *B. cenocepacia* virulence, being involved in persistence *in vivo* ([@B11]) and to adherence to respiratory epithelia ([@B20]). Moreover, the *cblA* gene is a useful marker for the *B. cenocepacia* ET12 lineage and has been linked with both pathogenicity and epidemic behavior ([@B16]). Thus, our data demonstrate that 8b mimics the effects of the deletion of *cepI*, confirming that the effects of the compound clearly rely on CepI inhibition.

Identification of the Diketopiperazine 8b Binding Site on CepI Enzyme
---------------------------------------------------------------------

As no structural data on *B. cenocepacia* CepI are available, to improve the possibility of 3D structure-assisted optimization of the non-competitive inhibitor 8b, we previously generated a homology model of the enzyme and performed *in silico* docking studies, which enabled the identification of multiple candidate binding sites for the inhibitor ([@B21] and "Supplementary Materials and Methods"). In particular, 8b could be docked with high score in at least three different pockets on the enzyme surface (**Figure [3A](#F3){ref-type="fig"}**). To understand if the inhibitor effectively binds to these sites, we therefore generated three different CepI mutants: S41R, Q46R, and S147R.

![Identification of the 8b binding site on CepI. **(A)** Cartoon representation of the CepI homology model showing three candidate binding sites, according to extensive *in silico* docking experiments using the 8b compound performed as described in ([@B21]) and in "Supplementary Materials and Methods." We selected three amino acid residues S41, Q46, and S147, belonging to each pocket, for mutagenesis study. **(B)** Steady state kinetic analysis of the two active CepI mutants as a function of C8-ACP. **(C)** IC~50~ determination of 8b against CepI enzymes. ![](fphar-09-00836-i001.jpg): wild type; ![](fphar-09-00836-i002.jpg): S41R; ![](fphar-09-00836-i003.jpg): S41A; ![](fphar-09-00836-i004.jpg): Q46R. The bars represent the standard deviation. Median values of three biological replicates are reported.](fphar-09-00836-g003){#F3}

All mutants could be expressed and purified to homogeneity using the same procedure adopted for the wild type ([@B21]). Although these mutants were obtained with yields generally lower than wild type CepI, all proteins variants were found soluble. Moreover, CD spectra of the mutants did not show significant differences with that of the wild type, thus confirming that the introduced mutations did not affect the correct fold of the protein (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}).

Among these mutants, our biochemical experiments revealed that S147R was completely inactive (**Table [1](#T1){ref-type="table"}**). To ascertain if the lack of activity was due to the introduction of a bulky and positively charged residue, we produced a new S147L mutant. However, this mutant was also inactive (**Table [1](#T1){ref-type="table"}**), suggesting an essential role for the area around the amino acid 147 in the catalysis.

###### 

Enzymatic characterization of CepI mutants.

  Enzyme      *V*~max~ (s^−1^)   *K*~*m*~ (mM)   compound 8b IC~50~ (mM)
  ----------- ------------------ --------------- -------------------------
  Wild type   0.25 ± 0.009       0.068 ± 0.005   0.0072 ± 0.0002
  R24Q        0.16 ± 0.020       0.074 ± 0.026   0.147 ± 0.017
  E29Q        n\. a.^a^          n\. a.          n\. a.
  E40Q        0.09 ± 0.003       0.105 ± 0.001   0.053 ± 0.0026
  S41A        0.16 ± 0.007       0.081 ± 0.006   0.113 ± 0.011
  S41R        0.08 ± 0.010       0.113 ± 0.016   1.070 ± 0.075
  Q46R        0.18 ± 0.024       0.078 ± 0.013   0.0192 ± 0.0035
  S147L       n\. a.             n\. a.          n\. a.
  S147R       n\. a.             n\. a.          n\. a.

a

n.a. not active.

By contrast, the S41R and Q46R mutants did not show severe perturbations in their kinetic properties, showing *K*~m~ values unchanged respect to the wild type, and *k*~cat~ values two to three fold reduced (**Figure [3B](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). To understand whether any of these mutated residues could be involved in the binding of the inhibitor, we measured the IC~50~ of compound 8b toward each mutant enzyme. While Q46R was comparable to wild type CepI, S41R was practically insensitive to the compound (IC~50~ \> 1 mM) (**Figure [3C](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**), strongly suggesting an involvement of this residue in the mechanism of action of 8b. However, to ascertain if the high IC~50~ of the compound toward the S41R mutant was due to perturbations introduced by the bulky and positively charged arginine rather than to the lack of interaction with the serine, a more conservative mutant S41A was generated. This new mutant was still less sensitive to 8b, showing an IC~50~ 15-fold higher than that of the wild type (**Figure [3C](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**), thus confirming a direct involvement of Ser 41 in inhibitor binding.

We therefore decided to expand our investigation to other amino acids belonging to the surface of this pocket region. This region is proximate to a loop that adopts a variety of conformations in homologous AHL synthases, with possible implications in SAM binding. In particular, we studied the role of R24, E29, and E40, predicted to constitute contact platform for the compound or for serine 41. Each of these residues was mutated into a glutamine (**Figure [4A](#F4){ref-type="fig"}**). Once again all these mutants did not show significant alteration of the *K*~m~ values; a small reduction was detected in their *k*~cat~, with the exception of the E29Q which however displayed negligible enzymatic activity (**Figure [4B](#F4){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). Also in this case, the CD spectrum of E29Q did not show differences with respect to the wild type, thus excluding that the lack of catalytic activity is due to a misfolding of the mutant (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}).

![Identification of the CepI amino acid residues involved in 8b binding. **(A)** Cartoon representation of the CepI homology model showing the possible interaction of 8b with the residues in proximity to the serine 41. The three amino acid R24, E29, and E40 were selected for mutagenesis. **(B)** Steady state kinetic analysis of the two active CepI mutants as a function of C8-ACP. **(C)** IC~50~ determination of 8b against CepI enzymes. ![](fphar-09-00836-i001.jpg): wild type; ![](fphar-09-00836-i005.jpg): R24Q; ![](fphar-09-00836-i006.jpg): E40Q. The bars represent the standard deviation. Median values of three biological replicates are reported.](fphar-09-00836-g004){#F4}

By contrast, all the active mutants were significantly less inhibited by the 8b compound, showing IC~50~ values 10--15 fold higher respect to the wild type (**Figure [4C](#F4){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**).

These results confirmed that CepI residues located in this region have a direct role in the binding and in the mechanism of inhibition of 8b against CepI, and experimentally support our previous hypotheses driven by *in silico* analyses.

Discussion
==========

Quorum sensing inhibitors appear as very promising potentiators of the classical antibiotic therapy to treat dangerous infections such as those caused by *B. cenocepacia*, for which a lack of new solutions is massively reported ([@B13]; [@B19]; [@B22]). Searching in PubMed for "quorum sensing inhibitors" retrieves 51 results in the first 5 months of 2018, which shows the increasing interest in alternative routes to counteract the emergence of resistance among bacteria such as *Proteus mirabilis* ([@B30]), *Salmonella* ([@B9]), *Pseudomonas aeruginosa* ([@B1]), *Staphylococcus aureus* ([@B15]).

We recently reported the discovery of diketopiperazines as inhibitors of the QS synthase CepI of *B. cenocepacia*. Beside the *in vitro* effect on the purified protein, these inhibitors showed interesting *in vivo* phenotypes, being able to decrease the production of proteases, siderophores, and lowering the ability of *B. cenocepacia* to form biofilm. Moreover, they increased the survival of infected *C. elegans* ([@B21]).

Here, we further confirmed that the compound acts also intracellularly by comparing the proteomes of the wild type *B. cenocepacia* J2315 untreated and treated with 25 μM 8b, with that of the Δ*cepI* knock-out strain. Indeed, these last two cultures showed the same proteomic profile: in our experimental conditions, only the over production of the giant cable pilus protein CblA was detected. Cable pilus is a well known virulence factor, which together with the 22-kDa pilus-associated adhesin is mainly involved in binding of the host cells and, particularly, in the transmigration across the epithelium ([@B28]). However, no relationship between CepI and CblA has been reported so far. Thus, this result is quite unexpected and why the lack or inhibition of the QS synthase should enhance the expression of this virulence trait of *B. cenocepacia* is an intriguing open question which is worth investigating deeper.

In our previous work, we computationally generated an homology model of *B. cenocepacia* CepI and performed *in silico* docking procedures, which enabled the identification of three candidate binding sites for the most promising diketopiperazine compound 8b ([@B21]). To confirm the involvement of these pockets into 8b binding, we initially designed three different CepI mutants: S41R, Q46R, and S147R. As expected from homology model analysis, our biochemical experiments revealed that the area surrounding the amino acid 147 is likely involved in catalysis due to strong proximity of this residue to the main access cavity hosting the acyl-ACP substrates (**Figure [3A](#F3){ref-type="fig"}**). Intriguingly, mutant S41R was practically insensitive to the 8b compound, suggesting that the pocket around this residue may form the binding site of the compound. Thus, to confirm this, three other mutants were generated by modifying the charged residues (R24, E29, and E40) around S41 into the polar, uncharged glutamine. Mutation E29Q abolished CepI enzymatic activity, suggesting roles for this residue in catalysis despite its distance from the enzyme's catalytic site. The other two mutants did not show significant alteration of the kinetic properties, nevertheless they were significantly less susceptible to inhibition by the 8b compound, confirming the mechanism of action and the involvement of the pocket in 8b binding.

Comparisons with homologous AHL synthases TofI ([@B5]) and LasI ([@B12]) structures indicate that CepI loop comprising neighboring residues 30--41 may be involved in conformational changes associated to interactions with the SAM substrate. These conformational changes may involve partial unfolding of the last helical turn comprising the fully conserved E29 residue. In this respect, isosteric alterations of the negatively charged character of this amino acid may result in increased structural instability and, possibly, interfere with the productive conformational changes necessary for SAM substrate binding (**Figure [5](#F5){ref-type="fig"}**).

![Identification of CepI mutated residues based on structural similarity with the crystal structures of homologous AHL synthases TofI ([@B5]) (orange) and LasI ([@B12]) (blue). The position of the SAM substrate, derived from the crystal structure of TofI in complex with an analog, is shown with magenta ball-and-sticks. The position of residues 24, 29, 40, 41, and 46 are shown with black arrows. The amino acid composition of this region is partially conserved among AHL synthases, as highlighted in the bottom panel, in which the fully conserved residues are evidenced, while conservative changes are in red.](fphar-09-00836-g005){#F5}

Residue S41, identified as the most susceptible to compound 8b inhibition, is located at the C-terminal hinge of the flexible loop possibly subject to conformational changes upon SAM binding (**Figure [6](#F6){ref-type="fig"}**). Introduction of bulky, positively charged residues at this site (such as in the S41R mutant) may introduce strong repulsion due to interference with neighboring Arg21 and Arg25 residues and may possibly explain the dramatic variation observed in IC~50~ values (**Table [1](#T1){ref-type="table"}**). Notably, homologous TofI possesses a Lys residue at this site, but at the same time its corresponding residue at position 21 is not an Arg, but a smaller Ser residue (**Figure [6](#F6){ref-type="fig"}**).

![Comparison of the amino acid network surrounding residue 41 in CepI and TofI. Shown is a superposition of the CepI homology model (light blue) with TofI crystal structure ([@B5]) (orange). Amino acid side chains are shown as sticks and labeled according to their numbering in both CepI and TofI. The position of the SAM substrate analog, as derived from TofI crystal structure, is shown as magenta ball-and-stick.](fphar-09-00836-g006){#F6}

Together these results support our previous finding and confirm that compound 8b acts intracellularly by inhibiting CepI activity, thus interfering with the production of the QS signal molecule C8-AHL. Moreover, the identification of the pocket involved in inhibitory mechanism of 8b provides new information on the binding of the compound with CepI, which will be useful for a structure-based optimization of the diketopiperazine inhibitors.
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